DOCSLIB.ORG

4Th DIA China Annual Meeting

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
4Th DIA China Annual Meeting ײࣷනٷ ˖࿋ڇࢇӸ 35(/,0,1$5< 352*5$0 ዐࡔᅅᄱࡔा঍ୁዐ႐ ',$ ዐࡔ౎ࣷ ຺াᄱ࿿႑တၹࣷڼ ႎظዐࡔᇑ๘হüüࢇፕᇑ WK',$&KLQD$QQXDO0HHWLQJ &ROODERUDWLRQ ,QQRYDWLRQLQ&KLQD ዐࡔฉ࡛ࡔाࣷᅱዐ႐ 6KDQJKDL,QWHUQDWLRQDO&RQYHQWLRQ&HQWHU&KLQD ౎ሆනȍȍጆ༶ಢჟ ౎ሆනȍȍࣷᅱԒߢĂ༪ஃĂቛબࢅஃ࿔ՄԒ 0D\3UHFRQIHUHQFH:RUNVKRSV 0D\&RQIHUHQFH([KLELWLRQDQG3RVWHUV WWW.DIACHINA.ORG John J. HU, PhD Vice President and General Manager, United States Pharmacopeia-China Welcome to 4th DIA China Annual Meeting in Shanghai! This year’s theme, “Collaboration and Innovation in China”, speaks to the fact that future pharmaceutical innovation is about collaboration, and China is an important member of the global innovation community that will contribute to this partnership. Thanks to the outstanding hard work of the program committee and DIA-China staff, we have added exciting new events to this year’s program. We are delighted and hon- ored to have Dr. Yin Li, the commissioner of SFDA, and two distinguished international thought leaders, Dr. David Ho and Dr. Alberto Grignolo as keynote speakers. For the first time, SFDA’s Center for Drug Evaluation (CDE), has agreed to conduct a town hall meeting that will allow meeting participants have an open and direct dialog with CDE. Working with China’s SFDA, US FDA and US Department of Commerce, we have also added two new API regulatory workshops at the preconference session. In addition, we are fortunate to be able to invite Japan’s PMDA to provide a special session focus- ing on recent regulatory policy development in the world’s second largest pharmaceu- tical market. New to this year’s program are dedicated tracks on biological and vac- cine development, CRO collaborations and China’s various high-tech parks that offer government incentives for pharmaceutical R&D activities. Through these programs and the DIA-China annual meeting platform, participants representing a wide range of professions – industry, government, academia, asso- ciations - will share views and knowledge, network and build new relationships. This event also brings together exhibitors from an equally wide variety of international stakeholders and partners. ࣌ᆓዂً Please join me at DIA China 2012 in Shanghai and I wish you all an enjoyable and pro- ductive meeting. John J. HU 4TH DIA China Annual Meeting Program Chairperson Welcome Note Note Welcome ቶჱਬ ዐࡔᅅᄱࡔा঍ୁዐ႐ዷඪ Ă߳࿋ઠՠǖڞ߳࿋ଶڦፎ৤ ຺াᄱ࿿႑တၹࣷڼ࿵ሆLj࿢்नॽ၎਋ሞฉ࡛LjࠌཞᆓઠĀڦሞ୴ᅪӇ඗ ዐࡔ౎ࣷLjཞ้Lj࿢்ڦ$,'ਸటăኄ๟࿢்๯ْሞฉ࡛ਉႜڦDŽ',$Džዐࡔ౎ࣷā ࠶૙ਆᆄ૰ਆ׊؜ဝԨْ౎ࣷăሞُLj࿢۽କࡔॆ๋೗ᄱ೗॔ڟᄥ൩ںᄺݥ׉ඵ႞ ࣌ᆓڦ࠼ଣ՗๖׵኿ڦ࿋ኮĊĊዐࡔᅅᄱࡔा঍ୁዐ႐Ljၠ߳࿋ڇ՗ࣷᅱዷӸپৈ ߌႇƽڦࢅዔ႐ ႎăĀๆܾ࿵ā೺क़Ljླྀ৊ᄱ೗ჺ৯ࢅظዷ༶๟ǖዐࡔᇑ๘হĊࢇፕᇑڦԨা౎ࣷ ڦႎᅅᄱׂᄽࣅظዘᄲ࠲॰ඪခăໜጣዐࡔڦႎ๟࿢ࡔአުሞᄱ೗ჺ݀ଶᇘظरຍ ऐᇜࢅ཈቟Ljժ൐ॽሁڦ௬ଣܔ๫ঙઠݴဆࢅᆌڦቛLjԨཱིഓᄽႴᄲሏᆩࡔाࣅ݀ ࣷᅱዐLjॽᆶઠጲࡔాྔአުڦࡔा৪ኛᇑࢇፕኮዐăሞྺ೺ෙཀڟᇑ֖ںܠઠሁ ჺ৯Ă*03Ăᄱ࿿ҾضጆॆĂბኁ৽ႎᄱჺ݀ĂଣڦևோĂბຍऐࠓࢅ዆ᄱᄽহ ࣆ༶঍ୁঢ়ᄓLjݴၛჺ৯ׯࡕăཞ้Ljࣷᅱ࣏༬՚ሺยڪඇĂ॔࠶አ֧तຕ਍࠶૙ ঍ୁࢅں௬ܔࢅጆॆ௬ڞଶڦॽᆶऐࣷᇑอೠዐ႐ॆٷକᄱ೗रຍอೠጆ༶Ljা้ ࣆ༶ăڦ༪ஃࠌཞߌ႗඀ ᅅڦཀLjዐࡔయ዁๘হৃڦLjࠅዚᄱ೗Ҿඇᅪ๎փ܏ेഽٷሞᅅᄱ๨ׇႴ൱փ܏ક ཈቟ăኄႴᄲ࿢்ࠌཞ౮૰ሞඓԍᄱ೗ዊଉڦٷ௬ଣጣሁઠሁۼᄱഓᄽࢅ॔࠶ऐࠓ ᅅᄱׂᄽۯႎᇑࢇፕೝ໼Ljओटླྀظڦമ༵ူLjਸྊ߸ྺ࠽ગࢅਸݣڦࢅᆩᄱҾඇ ॳ੃݀ቛăڦ Ă࠽ଶْ֫ܠቛLjਸቛ݀ڦዐࡔᅅᄱࡔा঍ୁዐ႐ᅃ኱ዂ૰ᇀྺዐࡔᄱ೗॔࠶๚ᄽ ރ႙ࡔाჺ༪ࣷஃ༇ٷڦዖႚ๕ܠࡔाࢇፕᇑ঍ୁă૦౎ઠLj࿢்ཚࡗਉӸڦᇘ ࿢்ઠܔ౎ࣷڦೝ໼ăԨْڦ঍ୁᇑࢇፕڦॺଆࡻٲࣷბຍ঍ୁࣷྺࡔాྔᅅᄱহ Ԩْࣷᅱዐᆶ໯ٗీۼਸ๔Lj࿢்ထྭᇑࣷ߳ݛڦႎظჽჄᄺ๟ਸྊڦཥدຫ़๟ ࣌ᆓዂً इᅮă ᇶ஢ׯࠀƽڥፌࢫLjᇨጁُْࣷᅱൽ ቶჱਬ ዐࡔᅅᄱࡔा঍ୁዐ႐ዷඪ Welcome Note Note Welcome ࣷᅱኮᅃLjᆖၚ૰ศڦٷ൶௅౎ࡀఇፌںዐࡔ౎ࣷ๟',$ሞዐࡔतჱ໿ ࠽ݘ࠲ጀࢅණ੗ăीሞԛ৙૶ჄׯࠀਉӸෙা౎ࣷኮڦࡔాྔᄽহڟᇺLjժ๴ ዷ༶Ljᇀڦႎđظ຺াዐࡔ౎ࣷॽྷජĐዐࡔᇑ๘হǖࢇፕᇑڼ$,'ࢫLj ౎ሆሞฉ࡛ࡔाࣷᅱዐ႐୉ዘਉӸă౎ࣷెᄥ൩ઠጲࡔాྔႎᄱჺ݀Ăᄱ॔և አުਦ֧࠳ᇵĂኪఁბኁĂጆॆࢅഓᄽڪĂბຍऐࠓतิׂ׍ॆںएضோĂଣ ࣆ༶ۅඤڦᄽহܠᕂଣࣷᅱăা้ઠՠॽྷජ౎ࣷዷ༶Ljࠌཞ༑༪ժቛྭዚॆ तዐࡔࢅ๘হ዆ᄱ݀ቛ൵๞ă ׇೝႜጆ༶ݴࣷLjԈઔጆ༶ಢჟĂጲܠዷ༶ᄇ঄तڦࣷยᆶ৛֒ٷԨْ ᇱڦஃ༇ĂᅜतᆯெࡔĂ౹ዞĂჱዞतዐࡔᄱ॔ևோࠌཞ֖ᇑۅᆯ๕ՑஃĂঋ ଶᇘतბ੔LjԈઔᄱ೗॔࠶݆ܠăጆ༶ࣷᅱࡥ߃ዚڪॠֱጆ༶ჺ༪ࣷ۽ଙᄱ॔ ాڪਸ݀ᇑᄱ࿿য়শĂຕ਍ཥऺत࠶૙ĂࣅბĂิׂतዊଉ੦዆ضୱ݆ࡀĂଣ ခĂᇱଙᄱޜᄽĂ&52ࢇፕᇑظ࣏ࣷॽሺे൶ᇘႠჺ݀Ăߛႎरຍᇴ൶ٷඹă ᅱ༶ăڪतॠᄓĂᅧ௭तิ࿿዆ᄱĂᅅଐഗႁĂገࣅᅅბׂิ ࣷăฺڦႎظᄥ൩౞ᕂଣُْዐࡔᄱ࿿ჺ݀ں׵኿$,' ኄ૛ᆖၚٗۅLj࠵ۅ࠵ٳዐࡔ౎ࣷĊĊ࿢்ሞኄ૛ၠࡔాतࡔྔᄽহ՗$,' ๘হă ײࣷᅱන ۅࡀ๚ခጆׇଋ݆ ࣮ࠥᇑቛྭڦ)'&$'(x ዐࡔ6 ࡀ৊ቛ݆ڦ$'x නԨ30 ੔ბਦ֧ĊĊ๟૙ၙ࣏๟၄ํǛڦ$'(x ெࡔ ࣷᅱႚ๕ڦႎᆗ ჺ৯ၹۙᇵضx ၭ႙Ցஃǖዐࡔଣ ਸ݀ĊĊ၄ํ࣏๟ഓಐضx ᇶጞ༪ஃǖᅅბ๚ခᇑଣ ଶᇘჺ༪ࣷܠბ੔ܠׇጆॆ༪ஃࢅࣷമܠ x Ԩা౎ࣷႎጆׇ ቛ݀ڦx &52 x ᅧ௭ᇑิ࿿዆೗ ႎĊĊఇ๕ᇑമৠظx ߛႎरຍᇴ൶ ᅳدConference Agenda Agenda Conference 5ሆ21-23නॽ༵ࠃཞำ ౎ሆන႓೺න_ࣷമჺ༪Ӭ ൶ᇘႎᄱჺ݀ܠටዖֶᅴत ࡀᄲ൱ᇑॠֱ݆ڦᄱ೗ᇱଙᄱ ߁౒ᇑํ७ڦ๬ᄓࠓॐዐǖऺ໙ऐࣅဣཥᄓኤضጱଣۉබࢇ*&3ዊଉࡀݔᇀ ඇཀ ض๯೺ଣ ၃ೠࠚࢅ࠶૙ޅ$'(༬ӄ૩࣮ࠥੂெࡔ܀๨ࢅዘႎฉ๨םగᄱ೗ฉ๨Ăٗ ᄲ൱ᇑํ७DŽ༬ᄥጆׇDžڦ+2ᅧ௭ᇨණኤ: एূࣷو߃ٳ࿋ǖዐࡔᅅᄱࡔा঍ୁዐ႐ࢅԲܻࢅ஽ଟڇၹӸ ڞ୿૙ᅅბԒߢጉႀኸ ӷཀ ኰᄽ݀ቛڦ৪ኛዐ ටዖֶᅴ੔ბڦDŽඇཀDžࣷമჺ༪Ӭᅃ DŽवଉၚᆌLjᆶၳႠࢅҾඇႠDžᆶ࠲ ںᄱ೗ਸ݀ժऺࣄၠഄ໱ڦ൶ࡔॆ৊ႜںሞᅃ߲ܔx କ঴ඇ൰ਸ݀ጒ઄ )DŽෙ֫Lj ᆖၚڦ൶ࡔॆጀ֩ ࢅํा֡ፕ࿚༶ض࠶ᄲ൱Ljཥऺბ࿚༶Ljଣ॔ڦ൶ᇘႎᄱჺ݀ x ༪ஃඇ൰ਸ݀ዐܠටዖֶᅴत ᇱሶڞඇ൰॔࠶ኸڦਸ݀ض൶ࡔॆଣںܠx ೠॏ࠲ᇀටዖֶᅴࢅ ঄๲ጆॆ ๴ᅮ֖ेኁ ࡓރձ๗ ᄱ૙ጆᄽටᇵLj݆ࡀ๚ခNjጀ֩๚ခටᇵض࣪෌DŽዐࡔDžჺ৯ਸ݀࣪෌࿴ࡲჺ৯ਸ݀ዐ႐޶ሴට x ᅅิLjิ࿿ཥऺጆᄽටᇵLjଣ മLjฉ๨മࢅฉ๨ࢫਸ݀ටᇵLjԈઔ,7ටᇵDžضࢲᕿঞ๲ x ዆ᄱ߾ᄽටᇵDŽଣ ᄱ૙ዐ႐ዷඪ x ࢇཞჺ৯ऐࠓضዐࡔၹࢅᅅᇾଣ Džڪx አުऐࠓDŽසᄱ೗อೠዐ႐ H. M. James HUNGձ๗ x ბຍჺ৯ऐࠓ ׊تتெࡔ)'$ᄱ೗อೠᇑჺ৯ዐ႐ิ࿿ཥऺ ૚࡛ᄊঞ๲ ๬ᄓऐࠓዷඪ DŽඇཀDžࣷമჺ༪Ӭܾضෙᅅᇾᄱ࿿ଣڼბٷԛ৙ (࿵֫Lj ჺ৯໯ޭ໯׊ضბଣٷԛ৙ ࡀᄲ൱ᇑॠֱ݆ڦBob POWELLձ๗ ᄱ೗ᇱଙᄱ ᄱ૙ߛपࠥ࿚ضஆ๧዆ᄱᆶ၌ࠅິDŽዐࡔDžଣ ྦྷಶ ঄๲ጆॆ ࠶૙ਆᄱ೗อೠዐ႐ᄽခ࠶૙ևၹۙᇵ۽ዐࡔࡔॆ๋೗ᄱ೗॔ John D. AYRESձ๗ ྦྷ࿴ԍձ๗ ૝ઠ዆ᄱDŽெࡔDžඇ൰࣒ኁҾඇߛपጺ॔ ெࡔఐਖ਼ࠅິఐਖ਼ჺ৯ํᄓ๪ิ࿿ཥऺᇑჺ৯ਦ֧੔ბևჱ໿൶ጺ॔ Jeffrey GREN ჺ༪Ӭ঻ถ ெࡔฆခևԍॳၩݯ೗Ӹࠅ๪ዷඪ ዐெฆஹ૴྿ࣷᄱ೗߾ፕፇெݛ૴ဝዷဝ ࡺਯࡔ ڦ൶ࡔჺ݀ᄱ೗ᅙঢ়ᆶକ௽ඓںܠᆖၚतڦටዖֶᅴܔৎๆ౎ઠLjࡔाฉ ටዖֶ ࣪෌ཨጨᆶ၌ࠅິඇ൰ഓᄽҾඇևჱ໿൶ጺ॔ڦٷ੔ბණ๎LjनሞदթĂᄱ೗वଉၚᆌĂଐၳࢅҾඇݛ௬٪ሞጣ࢔ ኸڦ࠲ᇀᄱ೗ᆶၳႠ ) +&,ڟݒᆙںණኪுᆶ࢔ࡻڦᅴֶܔ๟ኄၵڍᅴă DžLjᄺுᆶሞࡔॆ֫ Susanne KEITELձ๗ڦӲԨ๟ሞኄၵණኪኮമႚׯ)ڦ౎ᇱሶዐDŽڞ द ౹ዞ૙๚ࣷ౹ዞᄱ೗ዊଉࢅᅅଐׂ೗ਆਆ׊ڦᆯᇀටዖփཞׂܸิڦᇱሶዐ༹၄ăԨჺ༪ӬॽԒߢᅙঢ়ኪၬڞኸڦ௬ ዘᄲᅪᅭăԨӬᄺॽ༪ Chin Chin LIM ձ๗ڦթĂᄱ೗वଉၚᆌĂଐၳᅜतҾඇႠփཞሞ੔ბฉ ᅅࣅბत࿿૙ბํᄓ๪ዷඪ݆تᄱ೗ਸ ႎेೢ࿐ิ੔ბਆᆌᆩ੔ბև݆ᅅ੔ბڦටዖֶᅴ࿚༶ڟᇱሶ๢ᆩႠLjᅜत੊୯ڞᄱ೗ጀ֩ኸڦஃࡔॆ֫௬ ණڦփཞ๟ႎৎٷदթࢅᄱ࿿वଉၚᆌࣷሰׯ࢔ܔටዖֶᅴܔၜణă६ᇀ݀ Steven WOLFGANG ձ๗ ضଣڦᇀዖፃֶᅴܔණ๎࣏ࣷփ܏݀ቛăఫ஺LjڦටዖֶᅴܔLj੗ᅜᇨ९๎ ૙ޭپ߾ፕᆶనၵǛ ெࡔ)'$ᄱ೗อೠᇑჺ৯ዐ႐ᄱ೗Ҿඇྜኝतቻ࣮ևᇑํแኴႜևڦ๬ᄓLj॔࠶ኁࢅჺ݀ኁ߳ጲ և׊ ӸӬణՔ ቧ࿀ິ׊ ࠶૙ਆᄱ೗ጀ֩ິ۽ዐࡔࡔॆ๋೗ᄱ೗॔ x ණ๎ᇑदթDŽิ࿿ბLjට੨ბLj݀թ୲ࢅຶྨ୲DžLjᅜतᇑᄱ૙ᄱ࿿ ჺ༪Ӭ঻ถ ๴ᅮ֖ेኁ ࠶۽ኄ๟ᆯዐெฆஹ૴྿ࣷᄱ೗߾ፕፇLjெࡔฆခևतዐࡔࡔॆ๋೗ᄱ೗॔ ටᇵǖڦჺ৯ଶᇘ߾ፕضჺ༪ࣷăዐ ٗ๚ᇀူຎଣڦॠֱ۽࠶ࢅ॔॔ڦᄱ೗ᇱଙᄱܔኍڦ૙ਆDŽ6)'$Dž૴ࢇਉӸ ࠶૙ࢅሏႜضᄲ൱Ljํแ x ଣڦᄱ೗ᇱଙᄱ॔࠶ܔࡔ6)'$ࢅெࡔ)'$࠳ᇵॽ৽ዐெມݛణമ ዺޤ7ጆᄽत,ضx ଣ ڦጒ઄৊ႜ঻ถăᆯ౹ዞतჱዞᄱ೗॔࠶࠳ᇵतੵࡔ዆ᄱࠅິጨศጆॆፇׯ ႑တضᄱ೗ᇱଙᄱ॔࠶LjॠֱLj཈቟LjԈઔᄱ೗ᇱଙ x ଣڦጆॆፇᄺॽ༪ஃඇ൰ݔྷా ֱ॔ض࿚༶ăጆॆᇑ֖ࣷኁᄺॽ৽සࢆेഽඇ൰ x ଣڪऍሰ्ᇱଙᄱٶᄱྪฉၨ๳ᅜत ࠶ݛ݆ࢅ཰০ă x ᄱአ๚ခ॔ڦݛࢇፕ৊ႜᇶጞ༪ஃLjࠌฆᆶၳܠڦݛ௬ Ⴞײx ຕ਍࠶૙ࢅ ခฆ࠶૙ࢅኧ׼ޜضጱଣۉ ӸӬణՔ x x ᄱ೗ჺ݀ रຍኧ׼ڦჺ৯ऺ໙ऐࣅဣཥ၎࠲ضx କ঴ெࡔतഄ໱ࡔॆᄱ೗ᇱଙᄱ॔࠶ఇ๕ x ᇑଣ ࠶ቛྭ॔ڦᇱଙᄱܔ$'(x କ঴6 ܈႑ඪڦx ༵ߛዐࡔׂᇱଙᄱᆩᇀ዆व ዐࡔᇱଙᄱࣅბ೗ DŽඇཀDžࣷമჺ༪Ӭ຺ڦ࿄ঢ়಼ጚܔණ๎Ljेഽڦᇱଙᄱዊଉԍኤܔx ༵ߛ ኴ݆۽॔ڦᆩᇀ዆वิׂईሰ् *ෙ֫Lj ዘᄲႠڦऍሰ्ᇱଙᄱٶx ණ๎ਸቛࡔाࢇፕ ض๯೺ଣ ๴ᅮ֖ेኁ ჺ༪Ӭዷ׼ Džڪॠֱටᇵᅜतᄱॠටᇵ۽x ॔࠶ටᇵDŽอೠටᇵĂ॔ ᅅბձ๗چx $3,ิׂഓᄽටᇵ ቧ x ᄱ೗ჺ݀੔रටᇵࢅ࠶૙ኁ ݛܷᅅᄱ݀ቛᆶ၌ࠅິۭ๚׊ग़ጺ֋ x ዊଉԍኤࢅዊଉ੦዆Njॠᄓጆᄽටᇵ ዬ૬ࢤ߾ฆ࠶૙ຬ๗ DŽฉ࡛Džᅅᄱ੔रᆶ၌ࠅິ๯ဝኴႜ࠳ٳࠃᆌฆ ๔ڦx ༵ࠃ६՚्ᄱतփࢇ߭ᇱଙᄱॠ֪रຍ ঄๲ጆॆ DŽඇཀDžࣷമჺ༪Ӭෙ ࿵֫Lj- ࢲᕿঞ๲ ᄱ૙ዐ႐ዷඪض߁ ዐࡔၹࢅᅅᇾଣڦ๬ᄓࠓॐዐ˖ऺ໙ऐࣅဣཥᄓኤضጱଣۉබࢇ*&3ዊଉࡀݔᇀ ౒ᇑํ७ ঁᰵᢢᅅბձ๗ ॿ໋࢛෌዆ᄱᆶ၌ࠅິᅅბኴႜጺ॔ ঄๲ጆॆ ଠॆഋᅅბձ๗ ዐ႐ዷඪضᅅᇾ዗ୀ੔Lj,೺ଣٷ໼ྗ໼ Helena. Van den DUNGEN ౷ࣀ዆ᄱDŽ෌๗Dž'6 (ዊଉԍኤඇ൰޶ሴට Anthony TOLCHERᅅბձ๗ ჺ৯ጺ॔ضெࡔ67$5786ଣ Earl HULIHANঞ๲ ᅅბձ๗چெࡔ(:+XOLKDQጧკࠅິዷᄲࢇअට ቧ ݛܷᅅᄱ݀ቛᆶ၌ࠅິۭ๚׊ग़ጺ֋ ձ๗جି ൶݀ቛጺ॔ ჺ༪Ӭ঻ถںዐࣀٷ0HGLGDWD6ROXWLRQV:RUOGZLGH Beat E. WIDLERձ๗ ࠶૙ਆDŽᅜူ०׬6)'$Dž۽ೠॏႎᄱᅙঢ়ԥዐࡔࡔॆ๋೗ᄱ೗॔ڦ6FKLHPDQQࠅິࢇअට ੔ბᆶၳ ෌๗:LGOHU ٝܔჺ৯ዊଉ࠶૙ࣷᅱđฉምْഽۙăኄضĐࡔॆଣڦሞ౎ሆනቻਸ ༬՚ื༵ڦॺ૬Ljኝ༹ీ૰ڦႎࡔॆظခᇀޜਸ݀ժڦႎᄱ࿿đظٷჺ༪Ӭ঻ถ ৊Đዘ ૰༵ืਏᆶዘᄲᅪᅭăీڦ๟ሞዐࡔ৊ႜ๯ْට༹๬ᄓDŽ०׬),+Dž ܔ3ࢅᅃဣଚ࿔ॲࡀۨLjਸቛ&*ڦ౎ᅜઠLj࿐ิևࢅ6)'$Ӱքକዐࡔ Ⴞײ߳ዖᆌᆩڦჺ৯ضଣڟሏᆩ܈ጱຕ਍࠶૙ኟᅜट੺໏ۉऺ໙ऐࣅဣཥࢅ ॠֱă۽ණኤࢅዊଉ॔ڦჺ৯ऐࠓضჺ৯ă ଣضଣڦᆌᆩᅙޮ߃କඇ൰ᅜฉڦጱຕ਍֑णဣཥDŽ('&Džۉዐă ऺ໙ऐࣅဣཥ๑ᆩڦჺ৯ዐضଣܠഐ๔঩܎ă࢔تᆌᆩชڦ&')ܔዐࡔణമ ೺,ܔ๬ᄓยऺLjᅜतضଣڦႎᄱظჺ৯ඓํᆶᅃၵݛ௬Ⴔᄲ߀৊Ljසضଣ ዘᄲႠă඗ܸLj໱்ྫྫுᆶጀᅪڦ๴๬ኁܔຕ਍ዊଉࢅྜኝႠڟණ๎ۼኁ ݛ௬ăᅺُLj၎႑ਉӸ๯ْට༹๬ᄓڦ၃࠶૙ీ૰๟Բড཭؜ޅڦ๬ᄓضଣ دײሏᆩLjᅜतᇺڦႾࢅऺ໙ࣅဣཥײጱࣅᆌᆩۉDžڟDŽᄺႹ໱்ᅙঢ়ᅪ๎ ࠲॰ยऺᄲ൱Ljํแ཈቟Ljᅜतڟჺ༪Ӭݥ׉Ղᄲăჺ༪ӬాඹԈઔٗۨᅭ ᆖၚăڦຕ਍ዊଉࢅྜኝႠLjतഄթටҾඇႠԍቱ໯ሰׯܔ๼թටຕ਍੗ీ ă6)'$ᇀ౎ሆӰքକĖ࠲ᇀᄱ࿿,೺ଣۅ൶ጆᄽཞႜ঍ୁ࠵ںᇑԨ ݛ݆ڦ๑ᆩኁ்ీ૙঴ऺ໙ऐࣅဣཥᄓኤڦჺ༪Ӭॽ๑ऺ໙ဣཥڦԨْᅃཀ ޿ܔ࠳ᇵڦ$'(ᇱሶDŽ๬ႜDžཚኪėLjԨჺ༪Ӭᄺॽᄥ൩6ڞ๬ᄓ࠶૙ኸض ᇀ๢ᆩጒتऺ໙ऐࣅဣཥ৊ႜ߾ፕLjժీࠕփ܏ԍ׼ဣཥڦࢅሏᆩԥᄓኤࡗ ࿔ॲ৊ႜ঴܁ă ยऺĂ֪ڦऺ໙ऐࣅဣཥڦჺ৯ዐضༀăُྔLjԨჺ༪Ӭ࣏ॽ঻ถሏᆩᇀଣ ࿄ઠሏᆩ൵๞ࢅፌॅڦ੗ᅜᇨ९ܔ၄ႜՔጚăཞ้Lj࣏ॽڦ๬Ăሏႜࢅཽᅣ ӸӬణՔ ༬ႠLjԨჺ༪Ӭॽ༑༪ॺ܀ට༹๴๬ኁ৊ႜჺ৯ኄᅃܔࡀݔᇎᅜ঻ถăएᇀ ᄓኤఇ๕ăڦဣཥضጱଣۉ૬ᅃ߲๢ᆩᇀ߳ૌ ჺ৯ยऺᄲ൱Ljස'/7Lj07'Ljසࢆ჋ስഐ๔वଉLjضx କ঴),+࠲॰ଣ वଉڦ๬ᄓضසࢆླྀ४,,೺ଣ ࠲॰࿚༶ڦӸӬణՔ x ),+঩܎Ⴔᄲ࠲ጀ ݛ݆ڦ၃࠶૙ޅ x ࿋ںڦx ኪၬऺ໙ऐࣅဣཥᄓኤDŽ&69Džሞ*[3ዐ ت๬ᄓփཞኮض೺ଣ,ڦx ),+ᇑሞॳ੃๴๬ኁࢅթට༹ా৊ႜ ჺ৯ዐضਸ݀ଣܔ69ۨᅭࢅࡀݔLj༬՚๟ဣཥิంዜ೺DŽ6/&Dž&ڥۮ x ा֡ፕ཈቟ํڦ+,(ڦx ዗ୀթට ቨ੦ڦऺ໙ऐဣཥڦ໯ᆩዊଉԍኤ ᇱሶDŽ๬ႜDžཚኪė๥ڞ๬ᄓ࠶૙ኸضĖ࠲ᇀᄱ࿿,೺ଣڦx ౎Ӱք Քጚࡀݔࢅዊଉ༬ڦႾLjྺऺ໙ऐࣅဣཥײਏ༹ڦ७ํڗx ॺ૬๢ᆩᇀ࿔ ᅭ ԍቱ܈න׉ሏᆩ༵ࠃߛڦႠ ๬ᄓጒ઄ضଣ+,(ڦ൶ںx ჱዞࡔॆई Ⴔ൱ڦ๬ᄓยዃضĐ၄ํิऄđଣܔx ඓԍऺ໙ऐࣅဣཥ஢ፁᆩࢽ ๬ᄓض዗ୀ,೺ଣ+,(ڦx ሞ໼ྗ৊ႜ Ăࢇཞჺ৯ऐࠓDŽ&52VDžĂዐ႐ํᄓ๪Ăࢅጆᄽںჺ৯एضx ᆶዺᇀଣ x ࡣࡔLjႎेೢईၑߗ൧઄ ๬ᄓ߾ፕضခฆටᇵኧ׼ଣޜ ๴ᅮ֖ेኁ ჺ༪Ӭ঻ถ ጆᄽටᇵǖڦჺ৯ଶᇘ߾ፕض๚ᅜူଣٗ ჺ༪Ӭৃ౎๟ምْਉӸăዐࡔᅅბԒߢጉႀටڦߛೠॏڥइڦጆᄽටᇵ ኄ߲࠽ྺኪၬڦ๬ᄓߌ႗඀ض๯೺ଣܔ x Ԓߢፔ؜ዘᄲࠋ၅ăጉႀටᄲ൱ጚԢ߳ዖૌ႙ڦࡔाฉڟ՗݀ྺں࠶૙ࢅሏႜ ኟሞփ܏ضx ଣ ᄇ঄֌ଙLjࡔڦ࿔၅LjࡔाࣷᅱڦሜکሗኾڦߡॲăԈઔࡔाཞႜอለࡗڦ x ᅅბ๬ᄓ๚ခᅅბࠥ࿚ ჺ৯Ԓߢă৑࠶௅߲ߡॲᆶضଣڦ๬ᄓݛӄLjᅜतᆩᇀࡔाጀ֩ฤ൩ضाଣ ۽๬ᄓ॔ضx ଣ ୿૙ࡀݔጚԢăᅺُLjዐڤڢࢇޙՂႷӀቷۼ๟௅ᅃ߲ߡॲڍx ݆ࡀ๚ခ ഄਏ༹ᄲ൱Lj ᅅڦ୿૙ڤڢࢇޙණ๎ժፏ๰ړƽDžᆌڦᅅბԒߢጉႀටDŽԈઔඇ๘হڦമĂฉ๨മĂገࣅ੔ბDž ࡔضx ዆ᄱ߾ᄽDŽଣ ࿋ᅜڇ࡞ժ໦࡞ጉႀටĂჺ৯ླڟሶLjॽ๑թට࠲ࣉ๴ޏx ࢇཞჺ৯ऐࠓ ბԒߢጉႀࡀݔă ႑ăྰڦࡔॆڦतภत Ԩჺ༪ӬLj঄๲ጆॆॽǖ ዘᄲႠڦ୿૙ࡀݔڤڢDŽඇཀDžࣷമჺ༪Ӭ࿵ x ঻ถํाӄ૩ഽۙ ᇱሶLjՍᇀ֖ेኁৃࢫ๑ᆩڞࡔाኸڦ࿵֫Lj+ x ঻ถዘᄲ ୿૙ࡀݔDŽ૩ڤڢዘᄲڦፏ๰ړߡॲ้ᆌڦx ኸ؜ጉߡටሞጚԢփཞૌ႙ Ă࡛ՄԒĂ๮ߡDžೌڨჺ৯ԒߢĂ࿔ቌĂࣙض๬ᄓݛӄĂଣض၃ සLjଣޅ$'(࣮ࠥˈੂெࡔڦ༬ӄ૩܀๨ࢅዘႎฉ๨םగᄱ೗ฉ๨ǃٗ ؜Ӳࡀݔኮമࢅኮࢫॠᄓጲวڦ୿૙ڤࢇޙೠࠚࢅ࠶૙ x ๑ჺ༪Ӭ֖ेኁሞศ෇࣮ࠥ ኪ๎ڦሞ޿ݛ௬ቨ࿥ ᅅბጉႀઓవLjኄၵઓڦ୿૙ڤڢࢇޙ঄๲ጆॆ x ࠞ૤ჺ༪Ӭ֖ेኁ༪ஃසࢆ঴ਦ వ཈቟ࣷሞփณํा൧઄ዐ؜၄ ঄๲ጆॆ਩ྺெࡔ)'$ཞඦࣷׯᇵ ݛ๕஢ፁփཞბသႴ൱ăڦۯ঄๲ጆॆॽӀቷׯටბသᇱሶLj֑ᆩ঄๲ࢅࢻ ă܈ༀڦॽ༹၄࿔ࣅፎዘۯჺ༪Ӭऄ Mark J. GOLDBERGERᅅბձ๗ˈࠅࠌ࿐ิຬ๗ മெࡔ)'$ᄱ೗อೠᇑჺ৯ዐ႐ੇਪׂ೗ևև׊ ӸӬణՔ ெࡔ)'$ཞඦࣷׯᇵ ெࡔჯಢ዆ᄱ݆ࡀአ֧ޭጺ֋ ჺ༪Ӭ঳ຐ้Lj֖ेኁॽీࠕǖ ᅅბጉႀڦ୿૙ڤڢࢇޙڦፏ๰ࡔाฉණ੗ړᅅბጉႀටᆌڦFlorence HOUNᅅბձ๗ˈࠅࠌ࿐ิຬ๗ x ಒ܏ዐࡔ ࢇ૙Ⴀڦമெࡔ)'$ᄱ೗อೠᇑჺ৯ዐ႐ೠอෙևև׊ ࡀݔ ᇱሶڞࡔाኸڦᅅბጉႀࡀݔڦ୿૙ڤڢࢇޙ࠲ᇀ঻ถڦெࡔ)'$ཞඦࣷࡔाև૴ဝዷဝ x ኪၬዘᄲ ᅅბጉႀࡀݔڦ୿૙ڤڢࢇޙெࡔ෗ܻएᅺࠅິ݆ࡀአ֧ᇑ቟୼ޭጺ֋ x ሞጚԢ߳ዖૌ႙ߡॲ้Ljᆌᆩ ૚ጲ૰ᅅბձ๗ˈࠅࠌ࿐ิຬ๗ อೠፇፇ׊ ๴ᅮ֖ेኁضമெࡔ)'$ႎᄱଣ ெࡔ)'$ཞඦࣷࡔाև૴ဝዷဝ ெࡔఐਖ਼ࠅິDŽఐ෭۫Džႎ႗๨ׇጀ֧֩୼ኴႜጺ॔ x ᅅბጉႀට ๬ᄓᅅิضx ଣ ჺ৯ጆᄽටᇵضჺ༪Ӭ঻ถ x ଣ x ॔࠶ጀ֩๚ခටᇵ ߛपӬLjԈઔ঄ੜևݴĂڦएᇀӄ૩ჺ৯ڦ޿ჺ༪Ӭ๟ྺ೺ᅃཀDŽၭ้Dž ๨Ljፌࢫם༪ஃࢅଁသă঄๲ాඹ๟एᇀெࡔ࠲ᇀᅃ߲ᄱ೗಼ጚฉ๨Ljኮࢫ อೠ࠳ᇵत޶ሴටLjྜඇ֖ڦ$'(ă঄๲ጆॆሼঢ়๟ڢࠅਸԒڦᆼዘႎฉ๨ ăჺ༪Ӭݴྺෙ߲ևݴ৊ႜLj௅ևݴၭײ࠶ጀ֩ਦ֧ࡗ॔ڦ޿ᄱ೗ܔᇑକ ๨Ċምฉ๨ăם๨ĂᅜतםLjӀቷ้क़ຩႾࣄݴLjनฉ๨಼ጚമĂ಼ጚĊ้ ᆶ࠲୤ڦຕ਍ᅜत)'$ጧკ྿ᇵࣷڟ঻ถኮࢫLj֖ेኁॽੂ܌௅ᅃևݴ० ၟLj඗ࢫਸ๔༪ஃईঙ෥ӳᄇă ӸӬణՔ ࢅሏᆩإਦ֧ᇱሶएڦx କ঴ெࡔ)'$एᇀ੔ბ ၃૧ᅮݛ݆ࢅ߾ਏޅڦx କ঴ӻዺ॔࠶ਦ֧ ଆࡻ঍ୁڦዘᄲႠLjԈઔ዆ᄱഓᄽᇑ॔࠶ऐࠓኮक़ڦx କ঴ଆࡻอೠࡀݔ ࠏཚ ๴ᅮ֖ेኁ ጆᄽටᇵܸยڦ๟ྺਏᆶݿ޷ᄱ೗ਸ݀ঢ়ᄓࢅߛ຤ೝᆈᇕీ૰ײԨಢჟੜ ዆ڦ๬ᄓݛӄضࢇঢ়ᄓǖଣްڦLjူଚඪࢆଶᇘڦऺăᅃӯᄲ൱ᆶ౎ᅜฉ ၃ೠࠚ࠶૙ăཞ้ထޅ࠶૙ईᄱ೗ڦ๬ᄓض዆ۨLjଣڦLjᄱ೗ጀ֩቟୼ۨ ۯࢻڦײঢ়ᄓă६ᇀԨಢჟੜڦᆶሞ߾ፕዐईሞࣷᅱ঄သӬᆩᆈ࿔঄ᄇྭ ࡗටLjॽݴׯ߲ၭፇLjᅜԍגටຕႴᄲ੦዆Ljጺටຕփڦኁे֖ܔႠLj ኤಢჟၳࡕă DŽӷཀฉ࿷Džࣷമჺ༪Ӭ ,࿵֫Lj ڞ୿૙ᅅბԒߢጉႀኸ ঄๲ጆॆ Karen Woolley ձ๗ ዐࡔ3URVFULEHᅅଐཚრ๯ဝኴႜ࠳ ཀܾڼ ײ౎ሆන႓೺ܾ_ࣷᅱන ݴׇࣷᅃ ݴׇܾࣷ ݴׇࣷෙ ݴ຺ׇࣷ ݴׇࣷ࿵ ݴׇࣷୃ ቛ݀ڦჺ৯ᇑሏႜ ݆ࡀ๚ခ &0&*03 ཥऺ ᄱ࿿Ҿඇ &52ضଣ ᅃׇڼೝႜࣷᅱ ݴׇࣷ7 ݴׇࣷ7 ݴׇࣷ7 ݴׇࣷ7 ݴׇࣷ7 ݴׇࣷ7 ࿵֫Lj5B+C ࿵֫Lj5D+E ࿵֫Lj׊ॿཐ ෙ֫Lj3C+D ෙ֫Ljࣜࢋཐ ᅃ֫Lj๘ुཐ ቛ݀ڦतฉ๨ &52ሞዐࡔڦ๬ᄓኸళ ჺ݀ኁᆌ৊ႜض࠶૙ᝩ &'(ᄱ೗ጧკࣷঢ়ᄓ &0&ݛ୼तํ७ ݥଝၳႠଣڦ࠲ᇀ࣮Ԓ୲ ᄱ࿿য়ڦݴၛ तຩᆌยऺኸళ Ⴙ੗้໯׶౷ ڦڥሁณڦᄲஃ ሁܠ" শԒߢDŽ39Dž ˅ᅃ֫ˈࣀဲཐ ၶְ 10:00-10:30 ݴׇࣷᅃ ݴׇܾࣷ ݴׇࣷෙ ݴ຺ׇࣷ ݴׇࣷ࿵ ݴׇࣷୃ ቛ݀ڦჺ৯ᇑሏႜ ݆ࡀ๚ခ &0&*03 ཥऺ ᄱ࿿Ҿඇ &52ضଣ ׇܾڼೝႜࣷᅱ ݴׇࣷ7 ݴׇࣷ7 ݴׇࣷ7 ݴׇࣷ7 ݴׇࣷ7 ݴׇࣷ7 ࿵֫Lj5B+C ࿵֫Lj5D+E ࿵֫Lj׊ॿཐ ෙ֫Lj3C+D ෙ֫Ljࣜࢋཐ ᅃ֫Lj๘ुཐ ჺ৯LjԈض๬ᄓኸళ ႑ࡽॠ֪ሞႎ้೺ᄱ ภतራ೺ଣض੔ბਦ &0&ݛ୼ࢅํ७ĊĊ
Load more

Recommended publications
  • 2017 Sustainability Report
    2017 SUSTAINABILITY REPORT CREATING A BETTER WORLD CONTENTS WHO WE ARE CREATING A BETTER WORLD 4 About this Report 10 Business Overview 24 Our Goals 6 Letter from our CEO 13 Our Products 29 Our Planet 8 About Medidata OUR APPROACH GRI INDEX 14 Stalkholders 30-32 GRI Index 16 Materials References: PEOPLE FIRST Priority Issue: An issue deemed material to the company through our sustainability issue prioritization process. 18 Ethics Global Reporting Initiative (GRI): The GRI Sustainability Reporting Standards are the first and 20 Our People most widely adopted global standards for sustainability reporting. 22 Diversity Matters UN Global Compact: The UNGC is a voluntary initiative based on CEO commitments to implement universal sustainability principles and to understand partnerships in support of UN Goals. Sustainable Development Goals: The SDGs are a universal call to action to end poverty, protect the planet, and ensure that all people enjoy peace and prosperity. 2 2017 MEDIDATA SUSTAINABILITY REPORT 2017 MEDIDATA SUSTAINABILITY REPORT 3 CREATING A CREATING A WHO WE ARE OUR APPROACH PEOPLE FIRST BETTER WORLD GRI INDEX WHO WE ARE OUR APPROACH PEOPLE FIRST BETTER WORLD GRI INDEX About this Report Letter from our CEO About Medidata Business Overview Our Products About this Report Letter from our CEO About Medidata Business Overview Our Products ABOUT THIS REPORT As we reflect on the last 18 years, the spirit of No information contained on our website is innovation—one that has truly paved the way intended to be included as part of, or incorporated for better solutions, higher quality treatments, by reference into, this Annual Report on Form and quicker go-to-market times—remains our 10-k.
    [Show full text]
  • Semi-Annual Market Review
    Semi-Annual Market Review HEALTH IT & HEALTH INFORMATION SERVICES JULY 2019 www.hgp.com TABLE OF CONTENTS 1 Health IT Executive Summary 3 2 Health IT Market Trends 6 3 HIT M&A (Including Buyout) 9 4 Health IT Capital Raises (Non-Buyout) 14 5 Healthcare Capital Markets 15 6 Macroeconomics 19 7 Health IT Headlines 21 8 About Healthcare Growth Partners 24 9 HGP Transaction Experience 25 10 Appendix A – M&A Highlights 28 11 Appendix B – Buyout Highlights 31 12 Appendix C – Investment Highlights 34 Copyright© 2019 Healthcare Growth Partners 2 HEALTH IT EXECUTIVE SUMMARY 1 An Accumulating Backlog of Disciplined Sellers Let’s chat about fireside chats. The term first used to describe a series of evening radio addresses given by U.S. President Franklin D. Roosevelt during the Great Depression and World War II is now investment banker speak for “soft launches” of sell-side and capital raise transactions. Every company has a price, and given a market of healthy valuations, more companies are testing the waters to find out whether they can achieve that price. That process now looks a little more informal, or how you might envision a fireside chat. Price (or valuation) discovery for a company can range from a single conversation with an individual buyer to a full-blown auction with hundreds of buyers and everything in between, including a fireside chat. Given the increasing share of informal conversations, the reality is that more companies are for sale than meets the eye. While the healthy valuations publicized and press-released are encouraging more and more companies to price shop, there is a simultaneous statistical phenomenon in perceived valuations that often goes unmentioned: survivorship bias.
    [Show full text]
  • COVID-19 and Clinical Trials: the Medidata Perspective Release 7.0
    MAYJULY 18, 13, 2020 2020 COVID-19 and Clinical Trials: The Medidata Perspective Release 7.0 Copyright 2020 Medidata Solutions, Inc., a Dassault Systèmes company JULY 13, 2020 2 COVID-19 AND CLINICAL TRIALS: THE MEDIDATA PERSPECTIVE Table of Contents What’s New/What’s Significantly Updated in Release 7.0 3 Insights to Ongoing Data Capture in Clinical Trials 3 Regulatory Response 5 Impact to Medidata Customers, Patients and Trials 6 The Race for a Vaccine 7 Medidata Solutions to Assist Sponsors/Partners, Patients and Trials 10 Details on New and Adapted Medidata Solutions 11 Summary 18 Copyright 2020 Medidata Solutions, Inc., a Dassault Systèmes company JULY 13, 2020 3 COVID-19 AND CLINICAL TRIALS: THE MEDIDATA PERSPECTIVE What’s New/What’s Significantly Updated in Release 7.0 ā New: Metrics on new patients entering trials by country/region and therapeutic area by month ā Updated: Regulatory Response ā Updated:The Race for a Vaccine ā Updated: Summary table of the current vaccine clinical trials for COVID-19 ā Updated: Graphical Representation of COVID-19 Vaccination Trials ā Updated: Summary Insights to Ongoing Data Capture in Clinical Trials Medidata is continuously monitoring the global impact of COVID-19 on clinical trials. Our first data and insights impact report was released on March 23, with subsequent releases on April 3, April 17, May 4, May 18, June 15 and now July 13. At the beginning of the pandemic, we were looking at year-over-year changes to understand and grasp the magnitude of COVID-19 on the impact on clinical trials in terms of trial activity, across geographies and therapeutic areas (TAs).
    [Show full text]
  • Optimizing Clinical Trials: Concept to Conclusiontm
    2010 MEDIDATA SOLUTIONS MEDIDATA ANNUAL REPORT Optimizing Clinical Trials: Concept to ConclusionTM TWO THOUSAND 10ANNUAL REPORT At Medidata Solutions innovation is the key driver of our value. Medidataa Solutions is a leading global providerr of SaaSS clinical developmentdevelopmenen solutionsns that enhance the effiffi ciencyciee of customers’ clinical trialss from conceptncept to conclusion. Foror over 11 years, Medidata has consconsistentlys broughtught next-generationnext-gener innovationovation to the life sciescienceien industry to lower the total cost of clinical developmentevelopmen with technology that addressessses strategy and planning, resource management, study design and start-up, and study execution.cution. Tarek A. Sherif, Chairman & Chief Executive Offi cer Dear Medidata Shareholder: In our fi rst full year as a public time in our history. Our industry- company, we strengthened our leading tools are helping our clients position as the leading independent remove barriers to their productivity, SaaS (Software as a Service) vendor reduce the total cost of global in clinical development. By providing clinical development and accelerate By enabling our customers transformational clinical technology the time to bring life-enhancing drugs to optimize their clinical solutions, we generated strong top- to market. line growth, particularly from mid-size trials from concept to pharma and biotech customers and I am exceptionally proud of the way our CRO (contract research organiza- Medidata’s customer-facing teams conclusion, we are well tion) partners. We also experienced serve as trusted advisors to our dramatic bottom-line growth, with clients, emphasizing collaboration positioned to continue record earnings highlighting the and committing to their success. excellent operating leverage in our Medidata’s strong execution on our driving profi table business model.
    [Show full text]
  • (3BC) Event Optimizing the Role of Male Champions
    2018 Building Better Business Connections (3BC) Event Optimizing the Role of Male Champions FRIDAY, 4 MAY 8:30 AM – 3 PM New York Genome Center 101 Avenue of the Americas New York, NY 10013 HBAnet.org Event Sponsor 2018 HBA thanks its 2018 Corporate Partners. Together we are advancing the impact and influence of women A united force for change. in the business of healthcare. INFLUENCER LEVEL Purdue Pharma L.P. Momenta Pharmaceuticals, Inc. Pfizer Inc. Quest Diagnostics Ogilvy CommonHealth Worldwide RB Practice Fusion, Inc. Core purpose To further the advancement and impact of women in the PURPLE LEVEL Sanofi PwC business of healthcare. BD UCB, Inc. Regeneron Pharmaceuticals, Inc Bristol-Myers Squibb Company UPS Relypsa, Inc. Johnson & Johnson Vertex Pharmaceuticals Incorporated Roche Diagnostics Novartis Pharmaceuticals Walgreens Boots Alliance Sandoz Corporation Mission The Healthcare Businesswomen’s Association is a Shionogi, Inc. Publicis Health, LLC TEAL LEVEL global nonprofit organization comprised of individuals Strongbridge BioPharma plc Shire Abbott Stryker Corporation and organizations from across the healthcare industry Takeda Pharmaceuticals, Inc. Accenture Syneos Health committed to: GOLD LEVEL Alcon, a Novartis Company Syneos Health (f/k/a INC Res-inVentiv) Alnylam Pharmaceuticals Sysmex America, Inc. AbbVie Inc. • achieving gender parity in leadership positions AMAG Pharmaceuticals TBWA\WorldHealth Alexion Pharmaceuticals, Inc. Astellas Pharma US, Inc. Tesaro, Inc. Allergan • facilitating career and business connections Bulletin Healthcare Teva Pharmaceutical AmerisourceBergen Corporation Calcium USA The Lockwood Group LLC • providing effective practices that enable organizations Amgen Inc. CDM New York The Scienomics Group AstraZeneca/MedImmune to realize the full potential of their female talent Concentric Health Experience VMS BioMarketing athenahealth Daiichi Sankyo, Inc.
    [Show full text]
  • Clinical Researcher
    OCTOBER 2017 12 Getting on Board with ICH GCP E6(R2) 26 New European Medical Device Regulation 32 Clinical Trial Operations: Who is Watching? The Authority in Ethical, Responsible Clinical Research Regulations and Compliance: The Climb is Worth It See page 8 for exciting news about our next issue… Association of Clinical Research Professionals (ACRP) Professionals Research of Clinical Association www.acrpnet.org 10-Week CRA & CRC Beginner Program Meet The online 10-Week CRA & CRC Beginner Program provides a comprehensive introduction to clinical research and the job functions of the Clinical Research Associate (CRA) and Clinical Research Coordinator (CRC) for drug, biologic, and device trials. This program is geared toward individuals seeking a new career or career change into clinical research, Felix but haven’t decided which job track to pursue. Case studies and industry best practices are presented to emphasize how the learning objectives apply directly to the responsibilities of the CRA and CRC. Upon completion, Barnett will provide resume assistance so that you can position yourself for entry into this market. 2 years of service 31,526 miles traveled 3 countries of former residence Welcome to a different kind of CRO. rhoworld.com/careers BarnettInternational.com Customer Service: 800.856.2556 Meet Felix 2 years of service 31,526 miles traveled 3 countries of former residence Welcome to a different kind of CRO. rhoworld.com/careers CONTENTS October 2017 • Volume 31, Issue 5 • ISSN 2334-1882 6 Feature PEER REVIEWED GUEST EDITOR’S MESSAGE Regulations and Compliance: The Climb is Worth It Glenda Guest, CCRA, RQAP-GCP, TIACR Clinical Researcher is your platform.
    [Show full text]
  • COVID-19 and Clinical Trials: the Medidata Perspective Release 6.0
    MAYJUNE 18, 15, 2020 2020 COVID-19 and Clinical Trials: The Medidata Perspective Release 6.0 Copyright 2020 Medidata Solutions, Inc., a Dassault Systèmes company JUNE 15, 2020 2 COVID-19 AND CLINICAL TRIALS: THE MEDIDATA PERSPECTIVE Table of Contents What’s New/What’s Significantly Updated in Release 6.0 3 Insights to Ongoing Data Capture in Clinical Trials 3 Regulatory Response 5 Impact to Medidata Customers, Patients and Trials 6 The Race for a Vaccine 7 Medidata Solutions to Assist Sponsors/Partners, Patients and Trials 9 Details on New and Adapted Medidata Solutions 10 Summary 17 Copyright 2020 Medidata Solutions, Inc., a Dassault Systèmes company JUNE 15, 2020 3 COVID-19 AND CLINICAL TRIALS: THE MEDIDATA PERSPECTIVE What’s New/What’s Significantly Updated in Release 6.0 ā Updated: Metrics on new patients entering trials by country and therapeutic area (March, April and May) ā Updated: Regulatory Response ā New section: The Race for a Vaccine. ā Updated: Summary table of the current 10 vaccine clinical trials for COVID-19 ā New: Graphical Representation of COVID-19 Vaccination Trials ā Updated: Summary Insights to Ongoing Data Capture in Clinical Trials Medidata is continuously monitoring the global impact of COVID-19 on clinical trials. Our first data and insights impact report was released on March 23, with subsequent releases on April 3, April 17, May 4, May 18, and June 15. After an initial steep decline in clinical trial activity, both in terms of new patients entering clinical trials and visit rate per subject for ongoing trials, we are now starting to see a leveling off of the impact and regional fluctuations.
    [Show full text]
  • MEDIDATA SOLUTIONS (MDSO) BEST IDEAS LONG CALL January 16, 2015 DISCLAIMER
    TOM TOBIN ANDREW FREEDMAN MEDIDATA SOLUTIONS (MDSO) BEST IDEAS LONG CALL January 16, 2015 DISCLAIMER DISCLAIMER Hedgeye Risk Management is a registered investment advisor, registered with the State of Connecticut. Hedgeye Risk Management is not a broker dealer and does not provide investment advice for individuals. This research does not constitute an offer to sell, or a solicitation of an offer to buy any security. This research is presented without regard to individual investment preferences or risk parameters; it is general information and does not constitute specific investment advice. This presentation is based on information from sources believed to be reliable. Hedgeye Risk Management is not responsible for errors, inaccuracies or omissions of information. The opinions and conclusions contained in this report are those of Hedgeye Risk Management, and are intended solely for the use of Hedgeye Risk Management’s clients and subscribers. In reaching these opinions and conclusions, Hedgeye Risk Management and its employees have relied upon research conducted by Hedgeye Risk Management’s employees, which is based upon sources considered credible and reliable within the industry. Hedgeye Risk Management is not responsible for the validity or authenticity of the information upon which it has relied. TERMS OF USE This report is intended solely for the use of its recipient. Re-distribution or republication of this report and its contents are prohibited. For more details please refer to the appropriate sections of the Hedgeye Services Agreement and the Terms of Use at www.hedgeye.com HEDGEYE 2 PROCESS INVESTMENT PROCESS 1. Idea Generation - Relative and absolute performance - Valuation and sentiment - Battleground stocks and social media - Market research Fundamental 2.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________ FORM 10-K _____________________________________ ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34387 _____________________________________ Medidata Solutions, Inc. (Exact name of registrant as specified in its charter) _____________________________________ Delaware 13-4066508 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 350 Hudson Street, 9th Floor 10014 New York, New York (Address of principal executive offices) (Zip Code) (212) 918-1800 (Registrant's telephone number, including area code) Securities registered under Section 12(b) of the Exchange Act: Title of each class Name of each exchange on which registered Common Stock, par value $0.01 per share The NASDAQ Stock Market LLC Securities registered under Section 12(g) of the Exchange Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ý Yes ¨ No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ¨ Yes ý No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Drug Development Tools for Kidney Disease
    Drug Development Tools for Kidney Disease C-Path Overview Dr. Martha Brumfield Critical Path Institute 1 DDT-KD Topics Consortium • History of C-Path, What We Do and How We Do It • What DDT-KD Consortium Can Do and What It Will Not Do • C-Path Experience with Data Sharing and Aggregation • Example in Alzheimer’s Disease • Example in Polycystic Kidney Disease • C-Path Track Record 2 DDT-KD C-Path Mission Consortium • The Critical Path Institute is a catalyst in the development of tools to advance medical innovation and regulatory science, accelerating the path to a healthier world. We achieve this by leading teams that share data, knowledge, and expertise, resulting in sound, consensus-based science. 3 DDT-KD Critical Path Initiative Consortium Independent 501(c)3 founded in 2005 “… to foster development of new evaluation tools to inform medical product development” Memorandum of Understanding created between the FDA and C-Path in 2005 4 DDT-KD C-Path: A Public Private Partnership Consortium • Act as a trusted, neutral third party • Convene scientific consortia of industry, academia, and government for sharing of data/expertise The best science The broadest experience Active consensus building Shared risk and costs • Enable iterative EMA/FDA/PMDA participation in developing new methods to assess the safety and efficacy of medical products • Official regulatory endorsement of novel methodologies and drug development tools 5 DDT-KD C-Path Core Competencies Consortium • Regulatory qualification of preclinical and clinical biomarkers for
    [Show full text]
  • Life Sciences & Health Care M&A Update: Q2 2018
    Life Sciences & Health Care Quarterly update Q2 2018 Deloitte Corporate Finance LLC | www.investmentbanking.deloitte.com Quarterly Update | Q2 2018 | Life Sciences & Health Care Explosion of real world data in healthcare(1) In This Update Real world data (RWD) refers to heath care data gathered from a variety of sources outside of controlled clinical trials. These sources can include genomic ▪ Increasing need for data, data from health apps, wearables, and other biometric devices. This data-driven analytics information is used to generate real world evidence (RWE) and support data- driven, individualized health care reports. With the rise of digital and electronic fuels 2018 health care health care data comes a need for RWD management in the pharmaceutical transactions space. Deloitte RWE benchmarking survey findings(2) Also: This year Deloitte conducted its second annual survey of pharmaceutical ▪ Selected Recent Life companies’ perspectives regarding the advances in RWD management, RWE Sciences & Health Care value creation, and RWE applications. The survey results indicate that the (LSHC) M&A visibility and importance of RWE initiatives are increasing at the executive level. The survey found that most respondents are leveraging RWD across the Transactions enterprise to not only generate evidence, but also support other research, ▪ LSHC Sector Breakdown corporate, and commercial objectives. Other key findings include: and Analysis • Increasing importance of RWE integration: Many pharmaceutical companies are now leveraging RWD holistically throughout their ▪ Selected organizations to generate evidence and support patient research. Macroeconomic and • Growing data landscape: More so than ever, respondents are using Sector Data non-traditional data sources, such as purpose-built linked data, connected wearable technology, and health apps to drive decision making.
    [Show full text]
  • Medidata Solutions Partners with Veeva Systems to Bring Integrated Etmf to the Clinical Cloud
    Medidata Solutions Partners with Veeva Systems to Bring Integrated eTMF to the Clinical Cloud Cloud Technology Integration Gives Sponsors Path to Faster Regulatory Submissions NEW YORK, N.Y. – December 6, 2012 – Veeva Systems has partnered with Medidata Solutions (NASDAQ: MDSO) to offer the life science industry’s first cloud- based end-to-end solution that integrates clinical documentation and trial development. The two companies will integrate Vault eTMF, Veeva’s electronic trial master file (eTMF) content management application, across the Medidata Clinical Cloud, offering life science companies and their global partners a complete clinical technology solution with a searchable central repository for all clinical documentation. "Within the industry, there is an emerging demand for an eTMF to more consistently manage documents within a clinical trial,” said Alan S. Louie, Ph.D., research director, IDC Health Insights. “With the industry shift away from individual applications to more comprehensive eClinical solutions, seamless integration of applications and features such as eTMF into existing eClinical platforms should help leading life science companies to more fully and transparently manage overall trial efforts and improve process efficiencies." As clinical trials become more and more complex, the need for dependable document storage combined with real-time data accessibility is vital. The partnership will meet this need, advancing technology platform offerings in clinical development by facilitating efficient management of the trial master file collection. The integrated solution also provides secure document exchange between sites and sponsors, reducing the need for separate enterprise collaboration systems and portals. The collaborative nature of the clinical research team also demands a solution that is globally accessible and meets both regulatory and security needs.
    [Show full text]